GO
Loading...

Enter multiple symbols separated by commas

Stocks Bristol-Myers Squibb Co

More

  • Harvoni and a second hepatitis C drug, Sovaldi, together posted sales about $500 million above expectations and HIV medicine sales were higher-than-expected across all products, noted Edward Jones analyst Ashtyn Evans. Gilead, based in Foster City, California, said Tuesday that its net income was $4.49 billion, or $2.92 per share. Revenue soared to $8.24...

  • Pfizer Inc. beat Wall Street's second-quarter expectations and raised its 2015 forecast, as soaring sales for a few key products helped inoculate the world's second-largest drugmaker against a $1 billion revenue hit from foreign exchange rates and its last wave of cheap generic competition hurting former big sellers. Pfizer's experimental drugs "could...

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • LONDON, July 24- British spirits maker Diageo is under scrutiny in the United States, where the U.S. Securities and Exchange Commission has asked for information to see whether it shipped excess inventory to U.S. distributors, a practice known as "channel stuffing". A spokeswoman for Diageo, the world's biggest spirits company with brands including Smirnoff...

  • July 23- Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines. The company said it lost $130 million, or 8 cents per share, in the period. Company revenue rose 7 percent to $4.16 billion, about $400...

  • July 23- Bristol-Myers Squibb Co reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines. The U.S. drugmaker, which raised its full-year profit forecast because of the strong second-quarter results, on Thursday said it lost $130...

  • Surging sales for new cancer, heart and hepatitis C medicines helped drugmaker Bristol-Myers Squibb Co. beat Wall Street expectations, and it boosted its 2015 profit forecast. Still, a sizeable acquisition charge triggered a steep tax bill and a $130 million net loss in the second quarter. Bristol-Myers' recent purchase of startup Flexus Biosciences Inc....

  • July 23- Switzerland's Roche is lining up more new drugs to drive sales in a two-year window before cheap copycats of its biotech medicines hit the market, including a promising cancer immunotherapy it hopes to launch by late 2016.. The shares rose 1.1 percent by 0920 GMT on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive."

  • July 23- Switzerland's Roche expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio of new and established medicines. The shares rose 1.5 percent in early trading on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive." Its three top-selling cancer...

  • Bristol-Myers says HIV drug gets FDA incentives Tuesday, 21 Jul 2015 | 1:13 PM ET

    The Food and Drug Administration designated the drug BMS-663068 as a breakthrough treatment, so Bristol-Myers Squibb Co. will get extra meetings with the FDA and earlier communication with scientists as it studies the drug. There are six classes of HIV drugs, according to the National Institutes of Health, and patients are typically treated with drugs from...

  • The resignation of nine Toshiba executives, including the CEO, for doctoring books places the company beside the growing rogues' gallery of corporate desperados. The Houston company set a new standard for creative accounting practices. Tyco's CEO Dennis Kozlowski became the singular image of excess on Wall Street, throwing a $2 million birthday party for his...

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.

  • July 20- Bristol-Myers Squibb Co's Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer. Bristol-Myers shares rose 1.2 percent after the favorable separate announcements involving the...

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • Bristol's Opdivo found effective in kidney cancer Monday, 20 Jul 2015 | 8:30 AM ET

    July 20- Bristol-Myers Squibb Co said a late-stage trial testing Opdivo was stopped early after it was found beneficial in patients with the most common form of kidney cancer. An independent data committee recommended the trial be stopped, after it concluded that patients receiving Opdivo showed superior overall survival, compared to those who did not.

  • Your first trade for Tuesday Monday, 6 Jul 2015 | 6:13 PM ET
    Fast Money Final Trade: LLY, TLT, WTW & BMY

    The "Fast Money" traders give their final trades of the day.

  • As Christie eyes White House, New Jersey wants jobs Tuesday, 30 Jun 2015 | 11:32 AM ET

    NEW YORK, June 30- New Jersey Governor Chris Christie's second-in-command gave her pitch to a small crowd at a Philadelphia biotechnology convention in June with her signature move: giving out her cell phone number. "Now, no one from New Jersey! I want the guys that aren't already here in New Jersey. "

  • Your first trade for Tuesday Monday, 29 Jun 2015 | 6:19 PM ET
    Fast Money Final Trade:  COST, NXPI, RNF & SAVE

    The "Fast Money" traders give their final trades of the day.

  • Bristol-Myers to stop new antiviral drug research Thursday, 25 Jun 2015 | 11:08 AM ET

    June 25- Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.. Bristol-Myers' stock was up marginally at...